Top Markets
Coin of the day
RayzeBio, Inc. Common Stock RayzeBio, Inc. Common Stock

RayzeBio, Inc. Common Stock

RYZB
Rang în acțiuni #5675
RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs)... RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs) for oncology applications. Its primary therapeutic candidate, RYZ101, is currently advancing through Phase 3 clinical trials for the management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The company's innovative pipeline also features RYZ801, a distinct peptide engineered to deliver Actinium-225 (Ac225) by targeting GPC3, intended for treating hepatocellular carcinoma (HCC). Additionally, RayzeBio is developing RYZ811, a companion diagnostic imaging agent comprising a peptide binder, a chelator, and Gallium-68 (Ga68). Another active development program involves a novel proprietary small molecule designed to target CA9, delivering Ac225 for potential use against clear cell renal cell carcinoma (ccRCC). The firm was established in 2020 and is headquartered in San Diego, California.
Preț acțiune
$62.49
Ultima sincronizare: 2024-03-06
Capitalizare de piață
$2.52B
Schimbare (1 zi)
0.00%
Schimbare (1 an)
0.00%
Țară
US
Tranzacționează RayzeBio, Inc. Common Stock (RYZB)

Categorie

Raport P/S pentru RayzeBio, Inc. Common Stock (RYZB)
Raport P/S la data de 2026 TTM: 0
Conform celor mai recente rapoarte financiare și prețului acțiunilor RayzeBio, Inc. Common Stock, raportul P/S actual (TTM) este 0. La sfârșitul anului 2026, compania avea un P/S de 0.
Istoricul raportului P/S pentru RayzeBio, Inc. Common Stock din 2026 până în 2026
Raport P/S la sfârșitul fiecărui an
An Raport P/S Schimbă
Nu sunt suficiente date pentru perioada selectată.
Raport P/S pentru companii similare sau competitoare
Companie Raport P/S Diferență raport P/S Țara
10.17 -
US
10.13 -
NL
11.28 -
US
2.95 -
AU
- -
CH